GPCR

Sep 26

GPCR-Targeted Obesity Therapies: The Next Frontier Beyond GLP-1 Drugs

By Damian Medical Weight Loss

Takeaways Emerging GPCR-targeted therapies could offer oral, appetite-modifying weight-loss options with fewer GI side effects. GSBR-1290 shows real human efficacy (~5–7% weight loss) and convenience, while BRP highlights non-incretin, central-acting alternatives in preclinical…

Medical Weight Loss

GPCR-Targeted Obesity Therapies: The Next Frontier Beyond GLP-1 Drugs

Daxxify’s Role in Hormone-Sensitive Aesthetic Care

Testosterone Replacement Therapy

Daxxify’s Emerging Role in Hormone-Sensitive Aesthetic Medicine

Takeaways Daxxify offers significantly longer-lasting results (6–9 months) compared to traditional neuromodulators, making it especially appealing for patients with hormonal fluctuations. No peer-reviewed research yet exists linking Daxxify’s use to stabilizing estrogen-influenced dermal changes,…

Designer Estrogens 2.0: Tissue-Selective HRT Without Cancer Risk

Testosterone Replacement Therapy

Designer Estrogens 2.0: A New Era in Tissue-Selective Hormone Therapy

Takeaways Designer Estrogens 2.0 offer targeted bone and cognitive benefits while minimizing breast and uterine cancer risks. The 2025 UCSF Phase II trial shows improved bone density and memory with no evidence of…

CHECK OUT OUR BLOG HERE